Related Experiment Videos
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy
R Yarchoan1, J M Pluda, C F Perno
1Clinical Oncology Program, National Cancer Institute, Bethesda, Maryland 20892.
Annals of the New York Academy of Sciences
|January 1, 1990
Summary
Several dideoxynucleosides, including zidovudine (AZT), ddC, and ddI, effectively inhibit HIV replication by targeting reverse transcriptase. While offering therapeutic benefits, these drugs have associated toxicities that require careful management.
Area of Science:
- Pharmacology
- Virology
- Infectious Diseases
Background:
- Dideoxynucleosides like zidovudine (AZT), ddC, and ddI are key inhibitors of human immunodeficiency virus (HIV) replication.
- These drugs are phosphorylated intracellularly to active triphosphate forms that inhibit HIV DNA polymerase (reverse transcriptase).
Purpose of the Study:
- To review the efficacy and toxicity profiles of dideoxynucleosides as anti-HIV agents.
- To discuss the therapeutic windows and potential for dose-intensity, scheduling, and combination therapy to optimize treatment.
Main Methods:
- Review of existing clinical data and studies on dideoxynucleoside efficacy and toxicity.
- Analysis of the mechanism of action involving intracellular phosphorylation and reverse transcriptase inhibition.
Main Results:
- AZT demonstrates efficacy in reducing morbidity, mortality, and HIV-related dementia.
- ddC and ddI show promise in early studies for immunologic and virologic improvements in AIDS patients.
- Identified toxicities include bone marrow issues (AZT), peripheral neuropathy (ddC, ddI), and pancreatitis (ddI).
Conclusions:
- Dideoxynucleosides possess a therapeutic window for anti-HIV activity despite potential toxicities.
- Dose-intensity is a critical factor in dideoxynucleoside-related toxicity.
- Further research into optimized scheduling and combination therapies may enhance the therapeutic profiles of these agents.